Stockscreener 앱 받기
1.53
2.00%
0.03
시장 영업 전:
1.52
-0.01
-0.65%
전일 마감가:
$1.50
열려 있는:
$1.46
하루 거래량:
99,594
Relative Volume:
0.40
시가총액:
$62.92M
수익:
$1.88M
순이익/손실:
$-15.57M
주가수익비율:
-3.825
EPS:
-0.4
순현금흐름:
$-50.09M
1주 성능:
-6.13%
1개월 성능:
-23.12%
6개월 성능:
-32.60%
1년 성능:
-11.05%
1일 변동 폭
$1.38
$1.6596
1주일 범위
$1.38
$1.74
52주 변동 폭
$0.98
$3.44
Beyondspring Inc Stock (BYSI) Company Profile
명칭
Beyondspring Inc
전화
646-528-4184
주소
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
BYSI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
1.53 | 61.68M | 1.88M | -15.57M | -50.09M | -0.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-12-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-12-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-09-09 | 개시 | Robert W. Baird | Outperform |
| 2021-08-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-04-05 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-01-11 | 개시 | BofA Securities | Buy |
| 2020-12-29 | 개시 | Evercore ISI | Outperform |
| 2020-02-07 | 개시 | Jefferies | Buy |
| 2020-01-10 | 개시 | Nomura | Buy |
| 2019-12-03 | 개시 | William Blair | Outperform |
| 2019-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-30 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-10-25 | 재확인 | Maxim Group | Buy |
모두보기
Beyondspring Inc 주식(BYSI)의 최신 뉴스
Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI) - Defense World
Breakout Zone: How BeyondSpring Inc stock compares to market leaders2025 EndofYear Setup & Short-Term Trading Alerts - moha.gov.vn
Why BeyondSpring Inc. stock could benefit from AI revolutionVolatility Index Analysis & Free Significant Capital Appreciation - bollywoodhelpline.com
S P Trends: Does BeyondSpring Inc stock trade at a discount to peersMarket Movement Recap & Precise Swing Trade Alerts - moha.gov.vn
BeyondSpring Inc. (NASDAQ:BYSI) Sees Large Increase in Short Interest - MarketBeat
BeyondSpring (NASDAQ:BYSI) Shares Down 4.2% – Should You Sell? - Defense World
BeyondSpring (NASDAQ:BYSI) Trading Down 4.2%Should You Sell? - MarketBeat
Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Sahm
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Krystal Biotech (NASDAQ:KRYS) and BeyondSpring (NASDAQ:BYSI) Critical Survey - Defense World
Will BeyondSpring Inc. stock benefit from infrastructure spendingJuly 2025 Trade Ideas & Consistent Growth Equity Picks - Улправда
Can BeyondSpring Inc. stock weather global recessionJuly 2025 Breakouts & Weekly Return Optimization Alerts - Улправда
Will BeyondSpring Inc. stock benefit from sector rotationJuly 2025 Macro Moves & Breakout Confirmation Alerts - DonanımHaber
Will BeyondSpring Inc. stock benefit from AI adoptionMarket Weekly Review & Weekly Chart Analysis and Guides - Улправда
Pharma News: Will BeyondSpring Inc. stock outperform tech sector in 2025Quarterly Trade Summary & Low Risk Investment Opportunities - moha.gov.vn
Beyondspring Delays Second Closings of Share Sale - TipRanks
BeyondSpring Inc. Announces Preferred Share Purchase Agreement - TradingView — Track All Markets
BeyondSpring (NASDAQ: BYSI) now expects SEED share Second Closings in 1H 2026 - Stock Titan
BYSI: Recent Business Developments Shape Market Outlook - StocksToTrade
BeyondSpring Inc. Stock Shows Upward Spike As Earnings Report Uncovers Surprises - StocksToTrade
BeyondSpring Stock Faces Challenges Amid Recent Market Dynamics - timothysykes.com
BeyondSpring Inc. Faces Financial Pressure in the Pharmaceutical Market - timothysykes.com
BYSI Stock Shows Turbulence Amid Financial Uncertainty - StocksToTrade
BYSI Stock Volatility Amidst Strategic Developments and Market Shifts - StocksToTrade
BeyondSpring presents phase 3 DUBLIN-3 data at ESMO Asia Congress - MSN
BYSI’s Stock Roller Coaster: What Happens Next? - StocksToTrade
BeyondSpring Inc.’s Market Shift: Analyzing Financial Trends and Price Movements - timothysykes.com
BeyondSpring’s Stock Gains Steam Amid Market Developments - timothysykes.com
BeyondSpring Inc. (BYSI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
BeyondSpring (BYSI) Stock :Surges 5% as New Plinabulin Data Strengthens Case for Global NSCLC Registration Path - CoinCentral
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 - marketscreener.com
BYSI: BeyondSpring's Plinabulin Shows Promising Results in Phase 3 Trial - GuruFocus
BeyondSpring stock rises after positive Asian subset data from lung cancer trial - Investing.com Nigeria
BeyondSpring stock rises after positive Asian subset data from lung cancer trial By Investing.com - Investing.com South Africa
BeyondSpring reports positive Asian subset data for lung cancer drug By Investing.com - Investing.com Canada
BeyondSpring reports positive Asian subset data for lung cancer drug - Investing.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path - GlobeNewswire
BeyondSpring’s Plinabulin combination shows survival benefit in NSCLC - TipRanks
BeyondSpring (BYSI) Reports Promising Results for Plinabulin in Lung Cancer Study - GuruFocus
BeyondSpring Announces Positive Phase 3 DUBLIN-3 Results for Plinabulin in NSCLC Patients Post Anti-PD-(L)1 Therapy and Plans for Global DUBLIN-4 Trial - Quiver Quantitative
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 - marketscreener.com
BeyondSpring (NASDAQ: BYSI) DUBLIN-3 finds 15.8-month OS, fewer brain mets in NSCLC - Stock Titan
Why 22nd Century Group Inc stock could benefit from AI revolutionTrade Ideas & Accurate Buy Signal Notifications - moha.gov.vn
BeyondSpring Inc. Reports Q3 2025 Earnings and Strategic Shift - MSN
Beyondspring Inc (BYSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):